Tags

Type your tag names separated by a space and hit enter

Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Respir Med. 2006 Oct; 100(10):1781-90.RM

Abstract

Haemophilus influenzae is the most common bacterial pathogen associated with acute exacerbations of chronic bronchitis (AECB). This study determined the rate of bacterial eradication of H. influenzae during AECB treated with either macrolides or moxifloxacin. Adult AECB patients with H. influenzae were included in a pooled analysis of four double-blind, multicentre, randomised trials. Patients received either moxifloxacin (400 mg qd for 5-10 days) or macrolides (azithromycin 500 mg/250 mg qd for 5 days or clarithromycin 500 mg bid for 5-10 days). Bacterial eradication and clinical success were recorded at the test-of-cure visit (7-37 days post-therapy). Of 2555 patients in the intent-to-treat population, 910 were microbiologically valid and 292 (32%) had H. influenzae cultured at baseline. Bacterial eradication of H. influenzae was significantly higher with moxifloxacin vs. macrolide-treated patients (93.0% [133/143] vs. 73.2% [109/149], respectively, P = 0.001). Moxifloxacin also demonstrated higher eradication rates compared with azithromycin (96.8% vs. 84.6%, P = 0.019) and clarithromycin (90.1% vs. 64.2%, P = 0.001) analysed separately. Clinical success was 89.5% (128/143) for moxifloxacin vs. 85.2% (127/149) for the macrolide group (P = 0.278); similar results were found when moxifloxacin was compared individually with each macrolide. For patients with AECB due to H. influenzae, moxifloxacin provided superior bacterial eradication rates than macrolide therapy.

Authors+Show Affiliations

Department of Medicine, Winthrop-University Hospital, 222 Station Plaza North, Suite 509, Mineola, NY 11501, USA. mniederman@winthrop.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16531032

Citation

Niederman, M S., et al. "Eradication of H. Influenzae in AECB: a Pooled Analysis of Moxifloxacin Phase III Trials Compared With Macrolide Agents." Respiratory Medicine, vol. 100, no. 10, 2006, pp. 1781-90.
Niederman MS, Anzueto A, Sethi S, et al. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med. 2006;100(10):1781-90.
Niederman, M. S., Anzueto, A., Sethi, S., Choudhri, S., Kureishi, A., Haverstock, D., & Perroncel, R. (2006). Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respiratory Medicine, 100(10), 1781-90.
Niederman MS, et al. Eradication of H. Influenzae in AECB: a Pooled Analysis of Moxifloxacin Phase III Trials Compared With Macrolide Agents. Respir Med. 2006;100(10):1781-90. PubMed PMID: 16531032.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. AU - Niederman,M S, AU - Anzueto,A, AU - Sethi,S, AU - Choudhri,S, AU - Kureishi,A, AU - Haverstock,D, AU - Perroncel,R, Y1 - 2006/03/13/ PY - 2005/11/27/received PY - 2006/01/10/revised PY - 2006/01/29/accepted PY - 2006/3/15/pubmed PY - 2007/9/28/medline PY - 2006/3/15/entrez SP - 1781 EP - 90 JF - Respiratory medicine JO - Respir Med VL - 100 IS - 10 N2 - Haemophilus influenzae is the most common bacterial pathogen associated with acute exacerbations of chronic bronchitis (AECB). This study determined the rate of bacterial eradication of H. influenzae during AECB treated with either macrolides or moxifloxacin. Adult AECB patients with H. influenzae were included in a pooled analysis of four double-blind, multicentre, randomised trials. Patients received either moxifloxacin (400 mg qd for 5-10 days) or macrolides (azithromycin 500 mg/250 mg qd for 5 days or clarithromycin 500 mg bid for 5-10 days). Bacterial eradication and clinical success were recorded at the test-of-cure visit (7-37 days post-therapy). Of 2555 patients in the intent-to-treat population, 910 were microbiologically valid and 292 (32%) had H. influenzae cultured at baseline. Bacterial eradication of H. influenzae was significantly higher with moxifloxacin vs. macrolide-treated patients (93.0% [133/143] vs. 73.2% [109/149], respectively, P = 0.001). Moxifloxacin also demonstrated higher eradication rates compared with azithromycin (96.8% vs. 84.6%, P = 0.019) and clarithromycin (90.1% vs. 64.2%, P = 0.001) analysed separately. Clinical success was 89.5% (128/143) for moxifloxacin vs. 85.2% (127/149) for the macrolide group (P = 0.278); similar results were found when moxifloxacin was compared individually with each macrolide. For patients with AECB due to H. influenzae, moxifloxacin provided superior bacterial eradication rates than macrolide therapy. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/16531032/Eradication_of_H__influenzae_in_AECB:_A_pooled_analysis_of_moxifloxacin_phase_III_trials_compared_with_macrolide_agents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00059-X DB - PRIME DP - Unbound Medicine ER -